Evaluación y aceptación de los parches de microagujas (MAP) como una nueva forma de vacunación
Barra lateral del artículo
Contenido principal del artículo
Resumen
Journal Club
Descargas
Detalles del artículo
Citas en Dimensions Service
Citas
Berger MN, Davies C, Mathieu E, Shaban RZ, Bag S, Skinner SR. Developing and validating a scale to measure the perceptions of safety, usability and acceptability of microarray patches for vaccination: a study protocol. Ther Adv Vaccines Immunother. 2024;12:25151355241263560.
Soble A, Ko M, Gilchrist S, Malvolti S, Hasso-Agopsowicz M, Giersing B, et al. A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches. Vaccine. 2024; 42(6):1230-1246.
Hasso-Agopsowicz M, Spasenoska D, Jansen MPM, Masresha BG, Pastor D, Gebrekidan AH, et al. Exploring Important Attributes, the Potential Use Cases and Feasibility of Introduction of Measles and Rubella Microarray Patches (MR-MAPs): Insights from Nine Countries. Vaccines (Basel). 2024;12(9):1084.
Masoud D, Pierz A, Rauh L, Cruz AK, Palmedo C, Ratzan S. Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine trust. Vaccine. 2023;41(31):4616-4624.
Malas O, Tolsá MD. Needle-related Fear versus Vaccination Fear, Vaccination Intention, and Declared Reasons for Avoiding Vaccination. Clin Salud. 2022;33(3):101-107.
Ko M, Frivold C, Mvundura M, Soble A, Gregory C, Christiansen H, et al. An Application of an Initial Full Value of Vaccine Assessment Methodology to Measles-Rubella MAPs for Use in Low- and Middle-Income Countries. Vaccines (Basel). 2024;12(9):1075.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.